Piotr Chlosta

Prof. Piotr Chlosta

Jagiellonian University, Medical College, Krakow, Poland
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BM Zeeshan HameedBM Zeeshan Hameed
BM Zeeshan Hameed
Nithesh NaikNithesh Naik
Nithesh Naik
SISufyan Ibrahim
Sufyan Ibrahim
NTNisha Tatkar
Nisha Tatkar
MSMilap J. Shah
Milap J. Shah
BSBhaskar K Somani
Bhaskar K Somani
Artificial intelligence (AI) is an emerging technological system that provides a platform to manage and analyze data by emulating human cognitive functions with greater accuracy, revolutionizing patient care and introducing a paradigm shift to the healthcare industry. The purpose of this study is to identify the underlying factors that affect the adoption of artificial intelligence in healthcare (AIH) by healthcare providers and to understand “What are the factors that influence healthcare providers’ behavioral intentions to adopt AIH in their routine practice?” An integrated survey was conducted among healthcare providers, including consultants, residents/students, and nurses. The survey included items related to performance expectancy, effort expectancy, initial trust, personal innovativeness, task complexity, and technology characteristics. The collected data were analyzed using structural equation modeling. A total of 392 healthcare professionals participated in the survey, with 72.4% being male and 50.7% being 30 years old or younger. The results showed that performance expectancy, effort expectancy, and initial trust have a positive influence on the behavioral intentions of healthcare providers to use AIH. Personal innovativeness was found to have a positive influence on effort expectancy, while task complexity and technology characteristics have a positive influence on effort expectancy for AIH. The study’s empirically validated model sheds light on healthcare providers’ intention to adopt AIH, while the study’s findings can be used to develop strategies to encourage this adoption. However, further investigation is necessary to understand the individual factors affecting the adoption of AIH by healthcare providers.

20 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
JKJacek Kudelski
Jacek Kudelski
ATAnna Tokarzewicz
Anna Tokarzewicz
Monika Gudowska-SawczukMonika Gudowska-Sawczuk
Monika Gudowska-Sawczuk
Barbara MroczkoBarbara Mroczko
Barbara Mroczko
PCPiotr Chlosta
Piotr Chlosta
GMGrzegorz Młynarczyk
Grzegorz Młynarczyk
Introduction: Urinary bladder cancer is a serious oncological problem that is the cause of many deaths worldwide. The processes of metastasis and origination of local tumor invasion depend on the extracellular matrix (ECM) degradation. The cancer microenvironment, particularly the ECM, may be considered a key factor in cancer progression. Matrix metalloproteinases (MMPs) are classified as the main factors responsible for the degradation of ECM components. Therefore, the aim of the study was to evaluate the expression and activity of matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9) in urinary bladder cancer according to different stages. Material and methods: Urinary bladder tissue samples were analyzed. Cancer patients were divided into two groups: low-grade tumors (LG; Group I) and high-grade tumors (HG; Group II). Control tissue was obtained from the opposite site to the tumor. MMPs content and activity (actual and specific) were evaluated using ELISA and Western blot methods, respectively. Results: Both MMPs are present in high and low molecular complexes in healthy or bladder cancer tissues. The content of MMP-9 is enhanced in comparison with MMP-2, particularly in HG cancer tissue. The actual activity of MMP-2 was highest in LG cancer tissue whereas the actual activity of MMP-9 was highest in HG cancer. Specific activity of both MMPs was highest in LG cancer, but the activity of MMP-9 was higher in comparison with MMP-2. Conclusions: In conclusion, the content and specific activity of MMP-9 were increased in comparison with MMP-2. The revealed differences in content and activity of both MMPs demonstrate their different participation in ECM remodeling at different stages of cancer development. Moreover, it seems that MMP-9 has higher clinical utility than MMP-2 as a potential therapeutic option and a diagnostic biomarker of urinary bladder cancer.

15 July 2019 in BJU International
Verified
Journal Article
Open access
PDF file
BRBhavan Prasad Rai
Bhavan Prasad Rai
JBJasper Bondad
Jasper Bondad
NVNikhil Vasdev
Nikhil Vasdev
JAJim Adshead
Jim Adshead
TLTim Lane
Tim Lane
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
Background: It has been suggested that, in comparison with open radical cystectomy ( ORC ), robot‐assisted radical cystectomy ( RARC ) results in less blood loss, shorter convalescence and fewer complications, with equivalent short‐term oncological and functional outcomes; however, uncertainty remains as to the magnitude of these benefits. Objectives: To assess the effects of RARC vs ORC in adults with bladder cancer. Search Methods: We conducted a comprehensive search, with no restrictions on language of publication or publication status, for randomized controlled trials ( RCT s) that compared RARC with ORC . The date of the last search was 1 July 2018. Databases searched included the Cochrane Central Register of Controlled Trials, MEDLINE (1999 to July 2018), PubMed Embase (1999 to July 2018), Web of Science (1999 to July 2018), Cancer Research UK ( www.cancerresearchuk.org/ ), and the Institute of Cancer Research ( www.icr.ac.uk/ ). We also searched the following trial registers: ClinicalTrials.gov (clinicaltrials.gov/); BioMed Central International Standard Randomized Controlled Trials Number ( ISRCTN ) Registry ( www.isrctn.com ); and the World Health Organization International Clinical Trials Registry Platform. The review was based on a published protocol. Primary outcomes of the review were recurrence‐free survival and major postoperative complications (Clavien grade III to V). Secondary outcomes were minor postoperative complications (Clavien grades I and II ), transfusion requirement, length of hospital stay (days), quality of life, and positive surgical margins (%). Three review authors independently assessed relevant titles and abstracts of records identified by the literature search to determine which studies should be assessed further. Two review authors assessed risk of bias using the Cochrane risk‐of‐bias tool and rated the quality of evidence according to GRADE . We used Review Manager 5 to analyse the data. Results: We included in the review five RCT s comprising a total of 541 participants. Total numbers of participants included in the ORC and RARC cohorts were 270 and 271, respectively. We found that RARC and ORC may result in a similar time to recurrence (hazard ratio 1.05, 95% confidence interval [ CI ] 0.77 to 1.43; two trials, low‐certainty evidence). In absolute terms at 5 years of follow‐up, this corresponds to 16 more recurrences per 1000 participants (95% CI 79 fewer to 123 more) with 431 recurrences per 1000 participants for ORC . We downgraded the certainty of evidence because of study limitations and imprecision. RARC and ORC may result in similar rates of major complications (risk ratio [ RR ] 1.06, 95% CI 0.76 to 1.48; five trials, low‐certainty evidence). This corresponds to 11 more major complications per 1000 participants (95% CI 44 fewer to 89 more). We downgraded the certainty of evidence because of study limitations and imprecision. We were very uncertain whether RARC reduces minor complications (very‐low‐certainty evidence). We downgraded the certainty of evidence because of study limitations and very serious imprecision. RARC probably results in substantially fewer transfusions than ORC ( RR 0.58, 95% CI 0.43 to 0.80; two trials, moderate‐certainty evidence). This corresponds to 193 fewer transfusions per 1000 participants (95% CI 262 fewer to 92 fewer) based on 460 transfusion per 1000 participants for ORC . We downgraded the certainty of evidence because of study limitations. RARC may result in a slightly shorter hospital stay than ORC (mean difference −0.67, 95% CI −1.22 to −0.12; five trials, low‐certainty evidence). We downgraded the certainty of evidence because of study limitations and imprecision. RARC and ORC may result in a similar quality of life (standardized mean difference 0.08, 95% CI 0.32 lower to 0.16 higher; three trials, low‐certainty evidence). We downgraded the certainty of evidence because of study limitations and imprecision. RARC and ORC may result in similar positive surgical margin rates ( RR 1.16, 95% CI 0.56 to 2.40; five trials, low‐certainty evidence). This corresponds to eight more (95% CI 21 fewer to 67 more) positive surgical margins per 1000 participants, based on 48 positive surgical margins per 1000 participants for ORC . We downgraded the certainty of evidence because of study limitations and imprecision. Conclusions: We conclude that RARC and ORC may have similar outcomes with regard to time to recurrence, rates of major complications, quality of life, and positive surgical margin rates (all low‐certainty evidence). We are very uncertain whether the robotic approach reduces rates of minor complications (very‐low‐certainty evidence), although it probably reduces the risk of blood transfusions substantially (moderate‐certainty evidence) and may reduce hospital stay slightly (low‐certainty evidence). We were unable to conduct any of the preplanned subgroup analyses to assess the impact of patient age, pathological stage, body habitus, or surgeon expertise on outcomes. This review did not address issues of cost‐effectiveness.

Verified
Journal Article
Open access
PDF file
Nithesh NaikNithesh Naik
Nithesh Naik
TTTheodoros Tokas
Theodoros Tokas
Dasharathraj Kodu ShettyDasharathraj Kodu Shetty
Dasharathraj Kodu Shetty
BM Zeeshan HameedBM Zeeshan Hameed
BM Zeeshan Hameed
SSSarthak Shastri
Sarthak Shastri
BSBhaskar K Somani
Bhaskar K Somani
This review aims to present the applications of deep learning (DL) in prostate cancer diagnosis and treatment. Computer vision is becoming an increasingly large part of our daily lives due to advancements in technology. These advancements in computational power have allowed more extensive and more complex DL models to be trained on large datasets. Urologists have found these technologies help them in their work, and many such models have been developed to aid in the identification, treatment and surgical practices in prostate cancer. This review will present a systematic outline and summary of these deep learning models and technologies used for prostate cancer management. A literature search was carried out for English language articles over the last two decades from 2000–2021, and present in Scopus, MEDLINE, Clinicaltrials.gov, Science Direct, Web of Science and Google Scholar. A total of 224 articles were identified on the initial search. After screening, 64 articles were identified as related to applications in urology, from which 24 articles were identified to be solely related to the diagnosis and treatment of prostate cancer. The constant improvement in DL models should drive more research focusing on deep learning applications. The focus should be on improving models to the stage where they are ready to be implemented in clinical practice. Future research should prioritize developing models that can train on encrypted images, allowing increased data sharing and accessibility.

27 June 2015 in Urologia Internationalis
Verified
Journal Article
Open access
MCMichelle M. Carey
Michelle M. Carey
AZAbdullah Zreik
Abdullah Zreik
NFNeil J. Fenn
Neil J. Fenn
PCPiotr Chlosta
Piotr Chlosta
OAOmar M. Aboumarzouk
Omar M. Aboumarzouk
Introduction: The role of antibiotic prophylaxis for routine flexible cystoscopy (FC) is not clear due to the varying practices of individual clinicians. There are no formal guidelines, and this may be due to a lack of formal summary of the data. Methods: A systematic review was conducted in April 2014 including all randomised control trials on prophylactic antibiotic use for FC. The main outcome measures were confirmed bacteriuria on mid-stream urine (MSU), asymptomatic bacteriuria and symptomatic bacteriuria. A meta-analysis was conducted with difference between groups expressed as an odds ratio (OR) and control group risk. Results: 5,107 patients were included, 2,173 in placebo and 2,934 in the antibiotic group. The OR for all three outcomes favoured the antibiotic group; the risk of developing symptomatic bacteriuria was 0.06 times more likely in the control group (OR 0.34), 0.054 (OR 0.40) for developing asymptomatic bacteriuria and 0.109 for confirming bacteriuria on MSU (OR 0.36). The number needed to treat (NNT) was 15 (13-19) for MSU positive bacteriuria; 32 (27-42) for symptomatic bacteriuria and 26 (23-33) for asymptomatic bacteriuria. Conclusions: Antibiotic prophylaxis did confer a reduction in cases of symptomatic and asymptomatic bacteriuria but the NNT were high. Therefore, the authors cannot advocate the use of antibiotic prophylaxis for routine FC procedures.

9 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AMAkihiro Matsukawa
Akihiro Matsukawa
GLGiulio Litterio
Giulio Litterio
ACAngelo Cormio
Angelo Cormio
MMMarcin Miszczyk
Marcin Miszczyk
MPMehdi Kardoust Parizi
Mehdi Kardoust Parizi
TYTakafumi Yanagisawa
Takafumi Yanagisawa
Purpose: The addition of androgen receptor pathway inhibitors (ARPIs) to androgen deprivation therapy (ADT), with or without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC). Recently, the ARANOTE trial evaluated the efficacy and safety of Darolutamide + ADT in this setting. We aimed to update a network meta-analysis (NMA) of these combination therapies. Methods: We conducted a systematic search for RCTs on systemic therapies for mHSPC using MEDLINE, Embase, and the Web of Science Core Collection in September 2024. An NMA utilizing random-effects models was performed to compare progression-free survival (PFS), overall survival (OS), and adverse event (AE) incidence (PROSPERO: CRD42024591458). Results: A total of 12 RCTs (n = 11,954) were included in our NMAs. Triplet therapies were associated with significant improvements in PFS compared to ARPI-based doublet therapies (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.59–0.93; p = 0.01), but the difference did not reach the conventional levels of statistical significance for OS (HR: 0.82; 95% CI: 0.67–1.01; p = 0.059). In a subset analysis, compared to ARPI-based doublet therapies, triplet therapies showed a significant improvement in PFS in patients with high-volume disease (HR: 0.64; 95% CI: 0.47–0.88; p < 0.01), whereas no significant improvement was observed in those with low-volume disease (HR: 0.86; 95% CI: 0.45–1.67; p = 0.7). No significant difference in grade ≥ 3 AEs was observed between triplet therapies and ARPI-based doublet therapies. The main limitations include patient heterogeneity and limited follow-up in some studies. Conclusions: Triplet therapies can improve the oncologic outcomes of patients with mHSPC compared to ARPI-based doublet therapies, without significantly increasing severe AEs. These findings warrant further confirmation in a head-to-head trial powered for overall survival.